Literature DB >> 7420663

CSF carcinoembryonic antigen in meningeal carcinomatosis from breast cancer.

B S Yap, H Y Yap, H A Fritsche, G Blumenschein, G P Bodey.   

Abstract

Levels of CSF carcinoembryonic antigen (CEA) were determined in 23 patients with breast cancer and meningeal carcinomatosis. Levels greater than 1.5 ng/mL were observed in 16 patients; seven patients had undetectable levels. The meningeal disease of seven patients with elevated CSF CEA levels completely responded to treatment, and their CSF CEA levels concurrently decreased. Two patients whose meningeal disease responded poorly to treatment had persistently elevated levels of CSF CEA. In two other patients, a rising CSF CEA level was detected before there was any other evidence of meningeal relapse. Serial measurement of CSF CEA may play an important role in the clinical management of meningeal carcinomatosis in patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7420663

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  11 in total

Review 1.  Meningeal metastases: clinical aspects and diagnosis.

Authors:  F Formaglio; A Caraceni
Journal:  Ital J Neurol Sci       Date:  1998-06

2.  Changes of cerebrospinal fluid tumor marker levels may predict response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer.

Authors:  Christos Kosmas; Nicolas B Tsavaris; Georgia Soukouli; Panagiotis Gouveris; George Tsakonas; John Katselis; Heraklis Alexopoulos; Nicolas Mylonakis; Athanasios Karabelis
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 3.  Novel methods to diagnose leptomeningeal metastases in breast cancer.

Authors:  Lindsay Angus; John W M Martens; Martin J van den Bent; Peter A E Sillevis Smitt; Stefan Sleijfer; Agnes Jager
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

4.  Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors.

Authors:  A Twijnstra; B W Ongerboer de Visser; A P van Zanten; A A Hart; W J Nooyen
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

5.  Sensitivity and specificity of single and combined tumour markers in the diagnosis of leptomeningeal metastasis from breast cancer.

Authors:  A Twijnstra; A P van Zanten; W J Nooyen; B W Ongerboer de Visser
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-11       Impact factor: 10.154

6.  The clinical relevance of locally produced carcinoembryonic antigen in cerebrospinal fluid.

Authors:  C Jacobi; H Reiber; K Felgenhauer
Journal:  J Neurol       Date:  1986-11       Impact factor: 4.849

7.  Meningeal carcinomatosis from breast cancer: spinal cord vs. brain involvement.

Authors:  G Clamon; B Doebbeling
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

8.  Leptomeningeal carcinomatosis after major remission to taxane-based front-line therapy in patients with advanced breast cancer.

Authors:  Christos Kosmas; Nikolaos A Malamos; Nicolas B Tsavaris; Melina Stamataki; Stefanos Stefanou; Achilleas Gregoriou; Sofia Rokana; Maria Vartholomeou; Minas J Antonopoulos
Journal:  J Neurooncol       Date:  2002-02       Impact factor: 4.130

Review 9.  The detection and evaluation of human tumor metastases.

Authors:  D J Laurence; A M Neville
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

10.  Serum tumor marker levels at the development of intracranial metastasis in patients with lung or breast cancer.

Authors:  Naoya Ishibashi; Toshiya Maebayashi; Takuya Aizawa; Masakuni Sakaguchi; Masahiro Okada
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.